A stage-four cancer diagnosis once sounded like the end of the road – after all, there is no stage five. When Joe Biden’s ...

Lubbock native Juanita Lara was diagnosed with lymphoma and tongue cancer in April 2024, and went into chemotherapy shortly following at University Medical Center. In January ...

Explore the latest advancements in immunotherapies for T-cell lymphoma, addressing unique challenges and promising new ...

Relapsed/refractory peripheral and cutaneous T-cell lymphomas (R/R PTCL and CTCL) are aggressive blood cancers that often resist standard therapy. Patients with these lymphomas may require stem cell ...

Novel lymphoma microenvironment profiles presage response to CAR T-cell therapy in large B-cell lymphoma.

HOUSTON, June 17, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for ...

Marker’s unique T cell platform is strengthened by non-dilutive funding from U.S. state and federal agencies supporting cancer research.

Beloved Australian actor, Magda Szubanski, has revealed she's been diagnosed with a "very rare, very aggressive, very serious" blood cancer called mantle cell lymphoma.

Marker is currently investigating MT-601 in the Company-sponsored Phase 1 APOLLO trial (clinicaltrials.gov identifier: NCT05798897) for the treatment of patients with lymphoma who have relapsed ...

Preconditioning with lymphodepletion linked to stronger MAR-T cells response and suggests enhanced anti-tumor activity Highest enrollment since study launch underscores momentum and signals a ...

HOUSTON, May 20, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the ...

Breyanzi was approved in 2024 to treat a type of non-Hodgkin lymphoma called large B-cell lymphoma (LBCL). Below you’ll find common questions and answers about Breyanzi to help decide whether it ...